Business
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts – – Retrospective review shows revumenib was well tolerated as post-HSCT maintenance in children with KMT2Ar and NUP98r; all pts were alive and 90% (9/10) were relapse free at median follow-up of 19 months – – Ph 2 SAVE trial of revumenib with venetoclax/HMA in newly diagnosed NPM1m and KMT2Ar AML shows 86% ORR (18/21), 76% CR (16/21), and 100% (18/18) MRD negativity among responders – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m and KMT2Ar AML pts shows favorable tolerability and robust activity, including 92% (24/26) CRc – NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today highlighted key Revuforj® (revumenib) presentations spanning the acute leukemia treatment continuum that have been presented at the 67th American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, December 6-9, 2025. In total, Syndax and its collaborators will present 12 Revuforj abstracts at the 2025 ASH Annual Meeting. Revuforj is the Company's oral, first-in-class, FDA-approved menin inhibitor. “We are thrilled to share new data, including the first real-world evidence for the class, showing that revumenib is highly efficacious with a favorable safety profile in multiple acute leukemia subtypes and settings, including in combination with standard of care therapies. Notably, the datasets show deep responses in R/R and frontline NPM1m and KMT2Ar acute leukemia, as well as encouraging safety and early efficacy in post-HSCT maintenance,” said Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax. “With the initiation earlier this year of the pivotal frontline trial in patients unfit for intensive chemotherapy, and the recent initiation of our pivotal frontline trial in fit patients, Syndax is well positioned to further expand the clinical data supporting revumenib and lead in the frontline setting with this exciting new class of therapy.” Overview of Key Revumenib Data Presented at the 67th ASH Annual Meeting Early real-world experience with r...